Summary
- A follow-up of approximately 2 years involving several thousand patients with coronary heart disease (most of whom had type 2 diabetes), included in a placebo-controlled clinical trial of low-dose methotrexate, provides useful data for monitoring of patients taking methotrexate long-term.
- Compared to placebo, hepatic and gastro-intestinal disorders, and leukopenia were more frequently reported in patients on methotrexate. Hepatic disorders and skin cancer (particularly squamous cell carcinoma) were twice as frequent. There were also reports of cirrhosis.
©Prescrire 1 July 2021
Source: "Low-dose methotrexate: 2-year follow-up of adverse events" Prescrire International 2021; 30 (228): 187-188. Subscribers only.
|
Enjoy full access to Prescrire International, and support independent information
|